Novolin 70/30 is an over-the-counter medication used for controlling blood sugar in people with diabetes. It contains a short-acting insulin (regular insulin) and an intermediate-acting insulin (NPH insulin). The medicine is injected just under the skin twice a day, usually about 30 minutes before meals. Potential side effects include allergic reactions, hypoglycemia, and injection site skin reactions.
What Is Novolin 70/30?
Novolin® 70/30 (NPH insulin/regular insulin) is a non-prescription insulin medication used to treat diabetes. It contains a mixture of two different types of insulin: NPH insulin (Novolin N, an intermediate-acting insulin) and regular insulin (Novolin R, a short-acting insulin). Because it combines two types of insulin in one injection, using Novolin 70/30 can decrease the number of injections needed per day.
Insulin is actually a hormone that is naturally produced by the pancreas. This hormone is important for several functions, such as controlling blood sugar. Insulin helps the cells of your body remove glucose ("sugar") from your bloodstream. This sugar fuels your body's cells, giving them the energy they need to work properly. You may need to take insulin if your pancreas has trouble making enough, which is the case for people with type 1 diabetes and for some people who have type 2 diabetes.
Over the years, numerous different types of insulins have been developed to try to mimic the actions of the pancreas. As mentioned, Novolin 70/30 contains an intermediate-acting insulin (NPH insulin) and one that is short-acting (regular insulin). It starts working quickly and continues to work for several hours.
Written by/reviewed by: Kristi Monson, PharmD;Arthur Schoenstadt, MD
Last reviewed by: KristiMonson, PharmD;
List of references (click here):
Novolin 70/30 [package insert]. Princeton, NJ: Novo Nordisk, Inc.;2013 March.
Novo Nordisk. Dear healthcare provider letter: important insulin delivery device information: discontinuation of several insulin delivery devices (June 2009). FDA Web site. Available at: http://www.fda.gov/downloads/Drugs/DrugSafety/DrugShortages/UCM177158.pdf. Accessed August 21, 2009.
Food and Drug Administration, Center for Drug Evaluation and Research. Electronic orange book: Approved drug products with therapeutic equivalence evaluations. FDA Web site. Available at: http://www.fda.gov/cder/ob/. Accessed October 28, 2008.
Briggs GG, Freeman RK, Yaffe SJ. Drugs in Pregnancy and Lactation. 7th ed. Philadelphia (PA): Lippincott Williams & Wilkins; 2005.
eMedTV serves only as an informational resource. This site does not dispense medical advice or advice of any kind.
Site users seeking medical advice about their specific situation should consult with their own physician. Click